New research indicates the novel gene editing technique base editing could be used as a one-time therapy to restore the production of T cells in patients born with the rare genetic immune disorder CD3 delta severe combined immunodeficiency.
This condition, also known as CD3 delta SCID, is caused by a mutation in the CD3 delta gene, which produces a protein by the same name that is critical to the formation of T cells. Babies born with CD3 delta SCID are unable to produce these white blood cells that fight against disease-causing intruders in the body.